SHARES in Warner Chilcott gained more than 6% yesterday after the drugmaker said a second bidder has made a play for the company.

Northern Ireland drug maker Warner Chilcott has opened its books to a buyout consortium which made a bid approach worth around £1.5 billion earlier this month.

Northern Ireland-based drug company Warner Chilcott has said it has opened its books to the a consortium of private equity institutions that recently approached it.

Pharmaceutical giant Galen Holdings today announced it will change its name to Warner Chilcott.

GALEN HOLDINGS plans to complete its metamorphosis from an Irish pharmaceuticals group into a company focused on the US by changing its name to Warner Chilcott.

Northern-based drugmaker Galen Holdings has bought an exclusive licence for a generic version of its Ovcon 35 oral contraceptive from Barr Pharmaceuticals.

Northern pharmaceutical company Galen Holdings has said it bought an exclusive licence for a generic version of Galen's Ovcon 35 oral contraceptive from Barr Pharmaceuticals, for €19m

Northern drug company Galen Holdings has announced its Warner Chilcott subsidiary is to buy a manufacturing facility in Fajardo in Puerto Rico from Pfizer Inc.

Northern Ireland-based Galen Holdings is selling its British drug sales and marketing business for £40m to a company controlled by its founder, Dr Allen McClay.

Speciality pharmaceutical company Galen Holdings has sold its UK pharmaceutical product sales and marketing business for £40m (€59.8m).

The chief executive of Northern Ireland pharmaceutical company Galen Holdings, Roger Boissonneault, has sold off most of his shares in the company for just over $3m (€2.48m).

The Irish market began the week strongly, moving in line with the major European markets.

Northern Ireland pharmaceutical company Galen Holdings said today it has won three-year exclusivity for its Ovcon product.

Galen Holdings, the Northern Ireland holding company for a host of pharmaceutical companies, has sold its Pharmaceutical Development and Manufacturing Services business (PDMS) for £20m (€28.70m).

The US Food & Drug Administration has given final approval to a new form of oral contraceptive - Ovcon - manufactured by Northern Ireland speciality pharmaceutical company Galen Holdings.

SHARES in Galen Holdings increased by 3.81% yesterday after the company announced better-than-expected results in its final quarter.

The Dublin market was down this morning after share prices in CRH and Galen Holdings fell.

Galen Holdings has signed a letter of intent with Barr Laboratories removing the patent risk over three of its four products.

TRADING volumes in Dublin were light again with markets taking no clear direction, as investors awaited comments from the US Federal Reserve due yesterday evening.

Banks look set to dominate the British financial headlines next week when some of the UK’s best known high street names report half-year results.

The founder of Galen Holdings sold 700,000 shares in the company on Friday, netting over €7m, according to the London Stock Exchange today.

Galen Holdings has advised shareholders that it is in preliminary discussions which could lead to an offer for the company.

THE Irish market reflected the positive sentiment across Europe, gaining 47.43 points to 4327.59.

THE ISEQ index fell for a second day in succession, easing 7.85 points to 4257.11.

Pharmaceuticals business Galen Holdings has completed the acquisition of femhrt, the hormone replacement therapy.

ON a day when the ECB reduced interest rates

Northern Irish company Galen Holdings has paid £224m (€326m) to US pharmaceutical giant Pfizer for two female contraceptives and a hormone replacement therapy.

STOCKBROKERS expect Galen Holdings to deliver strong results tomorrow with Davy’s anticipating an 18% increase in product revenue growth.

Galen Holdings, the pharmaceuticals group based in Craigavon, Northern Ireland, is one step closer to marketing its new oral contraceptive, Ovcon, in the US.

IRISH stocks moved lower yesterday with the ISEQ index dropping 14.85 points to 3848.09.

The ISEQ index week ended negatively, dropping 33.80 points to close at 4226.29.

THE Irish market fell for the first day in five yesterday, losing 79.77 points to 4351.84.

The ISEQ index rose for the second consecutive day to close at 4376.40, a gain of 35.03 points.

SHARES in Dublin fell 24.23 points yesterday to close at 4312.46.

NORTHERN IRELAND pharmaceutical group Galen Holdings yesterday continued its three-year run of beating brokers’ forecasts.

IT was another quiet day on the Irish market yesterday, with the index creeping 22.96 points higher to 4078.88.

THE ISEQ closed 94.24 points lower at 3748.66 yesterday. News of a preliminary takeover approach to Abbey National

SHARES in Dublin followed European markets higher yesterday, closing 63.25 points stronger at 3926.35.

THE Irish Index of shares recovered 24.58 points yesterday, to close at 3863.1.

THE Irish Index of shares followed the global indices as it fell 64.28 points to 4205.08. Yet again the financials took the brunt of the fall as the financial market slipped 167.92 points lower to 8337.45.

THE ISEQ continued to climb yesterday, rising 67.49 points higher to close at 4355.68.

THE ISEQ index fell 145.04 points to 4214.67 yesterday.

THE ISEQ index slipped back 7.42 points to 4478.72 yesterday.